While BioNTech shares are currently trading near their 52-week lows, the Mainz-based biotechnology firm is signaling a significant operational shift. A major ...

In the midst of regulatory and political upheaval, biopharma’s R&D engine kept running, churning out highs and lows in equal ...

A number of diseases tend to peak in the winter, thanks to indoor gatherings that help germs spread. The list includes not ...

On December 14, 2020 I became the first person in the United States to receive the first FDA-approved COVID-19 vaccine. Now, ...

Despite trading near its 52-week low and posting a year-to-date loss of approximately 28%, BioNTech stock is attracting significant attention from major fina ...

BioNTech SE (NASDAQ:BNTX) is one of the best biotech stocks to buy according to Wall Street analysts. On December 8, Clear ...

BioNTech may be deeply ensconced in the latter stages of its bid to bring a COVID-19 vaccine to market, but it’s still pushing forward on other fronts, including a partnership with InstaDeep to deploy ...

BioNTech stock is a "Strong Buy", driven by positive phase 3 data for gotistobart in 2nd-line squamous NSCLC patients. Read ...

BioNTech and Bristol Myers Squibb share positive data from Phase 2 trial of pumitamig plus chemotherapy for triple-negative ...

Global interim Phase 2 data in locally advanced/metastatic triple-negative breast cancer (”TNBC”) show encouraging antitumor activity for ...

BioNTech and artificial intelligence start-up InstaDeep say they have developed an early warning system that can predict high-risk variants of COVID-19 from their genetic sequences much earlier than ...

BioNTech SE ( ($BNTX) ) has provided an update. On December 6, 2025, BioNTech SE and OncoC4, Inc. presented promising data from the non-pivotal ...